{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:46:06Z","timestamp":1789728366124,"version":"4.0.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81070999"],"award-info":[{"award-number":["81070999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaanxi Provincial Key R&D Program","award":["2022SF-380"],"award-info":[{"award-number":["2022SF-380"]}]},{"name":"Shaanxi Provincial Health Research Fund","award":["2022A006"],"award-info":[{"award-number":["2022A006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubiquitination, SUMOylation, and neddylation (collectively termed SUN modifications) play crucial roles in cancer pathogenesis and immunotherapy resistance. This study investigated the prognostic significance of these modifications in glioblastoma (GBM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Key genes associated with SUN modifications and anti-PD-1 resistance were identified using integrated bioinformatic approaches, including differential expression analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning algorithms. The expression levels of identified genes were subsequently validated in GBM cell lines using RT-qPCR and Western blotting. A prognostic risk model was constructed based on the key genes. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptome analysis were further employed to characterize gene expression patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six prognostic genes (PLK2, CDC73, PSMC2, SOCS3, ETV4, and LMO7) were identified. CDC73, PSMC2, SOCS3, and ETV4 were upregulated, while PLK2 and LMO7 were downregulated in GBM cells. The six-gene prognostic risk model demonstrated excellent predictive performance, achieving an Area Under the Curve (AUC) exceeding 0.9. The derived risk score exhibited significant correlations with clinical features, immune infiltration levels, and drug sensitivity profiles. Furthermore, scRNA-seq and spatial transcriptome analysis revealed high SOCS3 expression specifically in monocytes and macrophages, suggesting its potential role in mediating the activity of these immune cells to influence tumor progression and drug sensitivity in GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study established a robust six-gene prognostic model related to SUN modifications and anti-PD-1 therapy in GBM. The model demonstrates strong predictive ability and correlates with clinically relevant parameters, highlighting its potential utility for survival prediction and guiding therapeutic management decisions in GBM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15345-9","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:04:55Z","timestamp":1764417895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification and validation of SUN modification-related anti-PD-1 immunotherapy-resistance signatures to predict prognosis and immune microenvironment status in glioblastoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"8","key":"15345_CR1","first-page":"1231","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology. 2021;23(8):1231\u201351.","journal-title":"Neurooncology"},{"issue":"17","key":"15345_CR2","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842\u201350.","journal-title":"JAMA"},{"key":"15345_CR3","doi-asserted-by":"crossref","unstructured":"Hira VVV, Van Noorden CJF, Molenaar RJ. CXCR4 antagonists as stem cell mobilizers and therapy sensitizers for acute myeloid leukemia and glioblastoma? Biology. 2020;9(2):31.","DOI":"10.3390\/biology9020031"},{"key":"15345_CR4","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","volume":"80","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"15345_CR5","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","volume":"16","author":"MS Alghamri","year":"2022","unstructured":"Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, et al. Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy. ACS Nano. 2022;16(6):8729\u201350.","journal-title":"ACS Nano"},{"issue":"1","key":"15345_CR6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, et al. A Patient-Derived glioblastoma organoid model and biobank recapitulates Inter- and Intra-tumoral heterogeneity. Cell. 2020;180(1):188\u2013e204122.","journal-title":"Cell"},{"issue":"1","key":"15345_CR7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-023-01439-y","volume":"8","author":"X Wu","year":"2023","unstructured":"Wu X, Xu M, Geng M, Chen S, Little PJ, Xu S, Weng J. Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal Transduct Target Therapy. 2023;8(1):220.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"15345_CR8","first-page":"841","volume":"25","author":"G Chang","year":"2023","unstructured":"Chang G, Xie GS, Ma L, Li P, Li L, Richard HT. USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5. Neurooncology. 2023;25(5):841\u201353.","journal-title":"Neurooncology"},{"issue":"19","key":"15345_CR9","first-page":"e2309290","volume":"11","author":"Q Yue","year":"2024","unstructured":"Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo X, Yang T, Zhang M, Zuo B, Zeng T, et al. Histone H3K9 lactylation confers Temozolomide resistance in glioblastoma via LUC7L2-Mediated MLH1 intron Retention. Advanced science (Weinheim. Baden-Wurttemberg Germany). 2024;11(19):e2309290.","journal-title":"Baden-Wurttemberg Germany)"},{"issue":"3","key":"15345_CR10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"15345_CR11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/0008-5472.CAN-23-2664","volume":"84","author":"TA Lee","year":"2024","unstructured":"Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH, Lai YJ, Yamaguchi H, Li CW. Post-translational modification of PD-1: potential targets for cancer immunotherapy. Cancer Res. 2024;84(6):800\u20137.","journal-title":"Cancer Res"},{"issue":"7734","key":"15345_CR12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","volume":"564","author":"X Meng","year":"2018","unstructured":"Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, Liu H, Bai Y, Xue M, Hu R, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 2018;564(7734):130\u20135.","journal-title":"Nature"},{"issue":"1","key":"15345_CR13","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, et al. Neoadjuvant PD-1 Blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021;12(1):6938.","journal-title":"Nat Commun"},{"key":"15345_CR14","doi-asserted-by":"crossref","unstructured":"Pellegrino NE, Guven A, Gray K, Shah P, Kasture G, Nastke MD, Thakurta A, Gesta S, Vishnudas VK, Narain NR et al. The next frontier: translational development of Ubiquitination, SUMOylation, and neddylation in cancer. Int J Mol Sci. 2022;23(7):3480.","DOI":"10.3390\/ijms23073480"},{"issue":"14","key":"15345_CR15","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.7150\/ijbs.102051","volume":"20","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wang J, Zhao F, Li Y, Li Z, Li X, Chen A. SUMOylation modification of HNRNPK at the K422 site promotes invasion in glioblastoma. Int J Biol Sci. 2024;20(14):5715\u201330.","journal-title":"Int J Biol Sci"},{"key":"15345_CR16","doi-asserted-by":"crossref","unstructured":"Sun JX, An Y, Xiang JC, Xu JZ, Hu J, Wang SG, Xia QD. The Prognosis-Predictive and immunoregulatory role of sumoylation related genes: potential novel targets in prostate cancer treatment. Int J Mol Sci. 2023;24(17):13603.","DOI":"10.3390\/ijms241713603"},{"key":"15345_CR17","doi-asserted-by":"crossref","first-page":"1171811","DOI":"10.3389\/fimmu.2023.1171811","volume":"14","author":"Y Guo","year":"2023","unstructured":"Guo Y, Wu Z, Cen K, Bai Y, Dai Y, Mai Y, Hong K, Qu L. Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma. Front Immunol. 2023;14:1171811.","journal-title":"Front Immunol"},{"issue":"7216","key":"15345_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"CGAR Network","year":"2008","unstructured":"Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"D1","key":"15345_CR19","doi-asserted-by":"crossref","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM, Sisu C, Wright JC, Armstrong J, Barnes I, et al. GENCODE 2021. Nucleic Acids Res. 2021;49(D1):D916\u201323.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"15345_CR20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-019-0449-8","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Author correction: immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(6):1022.","journal-title":"Nat Med"},{"key":"15345_CR21","doi-asserted-by":"crossref","unstructured":"Smyth GK. limma: Linear Models for Microarray Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. edn. Edited by Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S. New York, NY: Springer New York; 2005: 397\u2013420.","DOI":"10.1007\/0-387-29362-0_23"},{"issue":"4","key":"15345_CR22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314\u20136.","journal-title":"Nat Biotechnol"},{"key":"15345_CR23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"15345_CR24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4097\/kja.19183","volume":"72","author":"J In","year":"2019","unstructured":"In J, Lee DK. Survival analysis: part II - applied clinical data analysis. Korean J Anesthesiology. 2019;72(5):441\u201357.","journal-title":"Korean J Anesthesiology"},{"issue":"1","key":"15345_CR25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, Wang L, Lu T, Zhang Y, Sun Z, et al. Machine learning-based integration develops an immune-derived LncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816.","journal-title":"Nat Commun"},{"issue":"11","key":"15345_CR26","doi-asserted-by":"crossref","first-page":"e18463","DOI":"10.1111\/jcmm.18463","volume":"28","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Wu F, Zhang W, Guo Y, Jiang X, Yan X, Ke Y. Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma. J Cell Mol Med. 2024;28(11):e18463.","journal-title":"J Cell Mol Med"},{"issue":"24","key":"15345_CR27","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.7150\/jca.35785","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang S, Tong YX, Zhang XH, Zhang YJ, Xu XS, Xiao AT, Chao TF, Gong JP. A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer. 2019;10(24):5944\u201354.","journal-title":"J Cancer"},{"issue":"11","key":"15345_CR28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"key":"15345_CR29","doi-asserted-by":"crossref","unstructured":"Hu D, Zhou M, Zhu X. Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer. BioMed research international 2019, 2019:2506843.","DOI":"10.1155\/2019\/2506843"},{"key":"15345_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biology (Clifton NJ). 2018;1711:243\u201359.","journal-title":"Methods Mol Biology (Clifton NJ)"},{"key":"15345_CR31","doi-asserted-by":"crossref","first-page":"607622","DOI":"10.3389\/fonc.2020.607622","volume":"10","author":"B Xiao","year":"2020","unstructured":"Xiao B, Liu L, Li A, Xiang C, Wang P, Li H, Xiao T. Identification and verification of Immune-Related gene prognostic signature based on SsGSEA for osteosarcoma. Front Oncol. 2020;10:607622.","journal-title":"Front Oncol"},{"issue":"43","key":"15345_CR32","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Database issue","key":"15345_CR33","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955\u2013961.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"15345_CR34","doi-asserted-by":"crossref","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.","journal-title":"PLoS ONE"},{"issue":"1","key":"15345_CR35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, Liu XS. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21.","journal-title":"Genome Med"},{"issue":"1","key":"15345_CR36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer Immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"D1","key":"15345_CR37","doi-asserted-by":"crossref","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, Wang H, Li T, Wang C. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023;51(D1):D1425\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"15345_CR38","doi-asserted-by":"crossref","first-page":"D1429","DOI":"10.1093\/nar\/gkad820","volume":"52","author":"W Zhou","year":"2024","unstructured":"Zhou W, Su M, Jiang T, Yang Q, Sun Q, Xu K, Shi J, Yang C, Ding N, Li Y, et al. SORC: an integrated Spatial omics resource in cancer. Nucleic Acids Res. 2024;52(D1):D1429\u201337.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"15345_CR39","first-page":"1572","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinf (Oxford England). 2010;26(12):1572\u20133.","journal-title":"Bioinf (Oxford England)"},{"issue":"2","key":"15345_CR40","doi-asserted-by":"crossref","first-page":"188616","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Et Biophys Acta Reviews Cancer. 2021;1876(2):188616.","journal-title":"Biochim Et Biophys Acta Reviews Cancer"},{"issue":"2","key":"15345_CR41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03675-6","volume":"151","author":"I Gomes","year":"2021","unstructured":"Gomes I, Moreno DA, Dos Reis MB, da Silva LS, Leal LF, Gon\u00e7alves GM, Pereira CA, Oliveira MA, de Medeiros Matsushita M, Reis RM. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with Temozolomide. J Neurooncol. 2021;151(2):135\u201344.","journal-title":"J Neurooncol"},{"issue":"1","key":"15345_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","volume":"16","author":"RI Enchev","year":"2015","unstructured":"Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 2015;16(1):30\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"15345_CR43","doi-asserted-by":"crossref","unstructured":"Tan S, Zhao J, Wang P. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells. Int J Oncol. 2023;63(2):94.","DOI":"10.3892\/ijo.2023.5542"},{"issue":"1","key":"15345_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13046-020-01750-4","volume":"39","author":"W Alafate","year":"2020","unstructured":"Alafate W, Xu D, Wu W, Xiang J, Ma X, Xie W, Bai X, Wang M, Wang J. Loss of PLK2 induces acquired resistance to Temozolomide in GBM via activation of Notch signaling. J Experimental Clin Cancer Research: CR. 2020;39(1):239.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"10","key":"15345_CR45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1080\/15548627.2024.2361574","volume":"20","author":"YD Chen","year":"2024","unstructured":"Chen YD, Lin XP, Ruan ZL, Li M, Yi XM, Zhang X, Li S, Shu HB. PLK2-mediated phosphorylation of SQSTM1 S349 promotes aggregation of polyubiquitinated proteins upon proteasomal dysfunction. Autophagy. 2024;20(10):2221\u201337.","journal-title":"Autophagy"},{"issue":"1","key":"15345_CR46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jgh.16815","volume":"40","author":"W Ge","year":"2025","unstructured":"Ge W, Wang Z, Zhong X, Chen Y, Tang X, Zheng S, Xu X, Wang K. PLK2 inhibited oxidative stress and ameliorated hepatic ischemia-reperfusion injury through phosphorylating GSK3\u03b2. J Gastroenterol Hepatol. 2025;40(1):304\u201314.","journal-title":"J Gastroenterol Hepatol"},{"issue":"25","key":"15345_CR47","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2023020144","volume":"142","author":"AF Melnick","year":"2023","unstructured":"Melnick AF, Mullin C, Lin K, McCarter AC, Liang S, Liu YE, Wang Q, Jerome NA, Choe E, Kunnath N, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159\u201374.","journal-title":"Blood"},{"issue":"9","key":"15345_CR48","doi-asserted-by":"crossref","first-page":"e29904","DOI":"10.1016\/j.heliyon.2024.e29904","volume":"10","author":"J Song","year":"2024","unstructured":"Song J, Guo W, Xu H, Gao T. CDC73 serves as a tumour-promoting factor in oesophageal cancer. Heliyon. 2024;10(9):e29904.","journal-title":"Heliyon"},{"issue":"4","key":"15345_CR49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1210\/clinem\/dgae909","volume":"110","author":"WF Simonds","year":"2025","unstructured":"Simonds WF, Li Y, Jha S. Genotype-Phenotype correlations in the Hyperparathyroidism-Jaw tumor syndrome. J Clin Endocrinol Metab. 2025;110(4):931\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"15345_CR50","doi-asserted-by":"crossref","unstructured":"Kim SY, Lee JY, Cho YJ, Jo KH, Kim ES, Han JH, Baek KH, Moon SD. USP37 deubiquitinates CDC73 in HPT-JT syndrome. Int J Mol Sci. 2022;23(12):6364.","DOI":"10.3390\/ijms23126364"},{"key":"15345_CR51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/PGPM.S418533","volume":"16","author":"W Huang","year":"2023","unstructured":"Huang W, Qian Z, Shi Y, Zhang Z, Hou R, Mei J, Xu J, Ding J. PSMC2 is a novel prognostic biomarker and predicts immunotherapeutic responses: from pancreatic cancer to Pan-Cancer. Pharmacogenomics Personalized Med. 2023;16:747\u201358.","journal-title":"Pharmacogenomics Personalized Med"},{"issue":"1","key":"15345_CR52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12957-022-02533-1","volume":"20","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wang Y, Wang D, Wan J, Qin X, Mu Z, Hu N. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells. World J Surg Oncol. 2022;20(1):84.","journal-title":"World J Surg Oncol"},{"key":"15345_CR53","doi-asserted-by":"crossref","first-page":"116755","DOI":"10.1016\/j.bcp.2025.116755","volume":"233","author":"PK Roy","year":"2025","unstructured":"Roy PK, Deepak K, Das CK, Das A, Biswas A, Jena BC, Mandal M. PSMC2 promotes resistance against Temozolomide in glioblastoma via suppressing JNK-mediated autophagic cell death. Biochem Pharmacol. 2025;233:116755.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"15345_CR54","doi-asserted-by":"crossref","first-page":"152802","DOI":"10.1016\/j.imbio.2024.152802","volume":"229","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang S, Zhao Z, Jin Q, Wang Z, Song Z, Liu L, Zhao Z. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K\/AKT\/mTOR pathway. Immunobiology. 2024;229(3):152802.","journal-title":"Immunobiology"},{"issue":"1","key":"15345_CR55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41389-022-00386-7","volume":"11","author":"T Liu","year":"2022","unstructured":"Liu T, Zhang J, Chen H, Bianba T, Pan Y, Wang X, Jiang Y, Yang Z. PSMC2 promotes the progression of gastric cancer via induction of RPS15A\/mTOR pathway. Oncogenesis. 2022;11(1):12.","journal-title":"Oncogenesis"},{"issue":"21\u201322","key":"15345_CR56","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1080\/15384101.2023.2293590","volume":"22","author":"J Su","year":"2023","unstructured":"Su J, Hu S, Ding S, Feng K. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway. Cell Cycle (Georgetown Tex). 2023;22(21\u201322):2381\u201391.","journal-title":"Cell Cycle (Georgetown Tex)"},{"issue":"2","key":"15345_CR57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s42000-018-0078-5","volume":"18","author":"JAB Pedroso","year":"2019","unstructured":"Pedroso JAB, Ramos-Lobo AM, Donato J Jr. SOCS3 as a future target to treat metabolic disorders. Hormones (Athens Greece). 2019;18(2):127\u201336.","journal-title":"Hormones (Athens Greece)"},{"issue":"2","key":"15345_CR58","doi-asserted-by":"crossref","first-page":"e0212581","DOI":"10.1371\/journal.pone.0212581","volume":"14","author":"MP Ventero","year":"2019","unstructured":"Ventero MP, Fuentes-Baile M, Quereda C, Perez-Valeciano E, Alenda C, Garcia-Morales P, Esposito D, Dorado P, Manuel Barbera V, Saceda M. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. PLoS ONE. 2019;14(2):e0212581.","journal-title":"PLoS ONE"},{"issue":"3","key":"15345_CR59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.celrep.2019.03.047","volume":"27","author":"G MacLeod","year":"2019","unstructured":"MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho FJ, Cavalli FMG, et al. Genome-Wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of Temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 2019;27(3):971\u2013e986979.","journal-title":"Cell Rep"},{"issue":"15","key":"15345_CR60","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/jcmm.17807","volume":"27","author":"L Dai","year":"2023","unstructured":"Dai L, Han Y, Yang Z, Zeng Y, Liang W, Shi Z, Tao Y, Liang X, Liu W, Zhou S, et al. Identification and validation of SOCS1\/2\/3\/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma. J Cell Mol Med. 2023;27(15):2194\u2013214.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"15345_CR61","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.31557\/APJCP.2023.24.6.1841","volume":"24","author":"M Sanaei","year":"2023","unstructured":"Sanaei M, Kavoosi F. The effect of 5-aza,2\u2019-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK\/STAT pathways in neuroblastoma and glioblastoma cells lines. Asian Pac J Cancer Prevention: APJCP. 2023;24(6):1841\u201354.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"12","key":"15345_CR62","doi-asserted-by":"crossref","first-page":"22272","DOI":"10.1002\/jcp.28794","volume":"234","author":"CH Xu","year":"2019","unstructured":"Xu CH, Liu Y, Xiao LM, Chen LK, Zheng SY, Zeng EM, Li DH, Li YP. Silencing microRNA-221\/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK\/STAT pathway. J Cell Physiol. 2019;234(12):22272\u201384.","journal-title":"J Cell Physiol"},{"key":"15345_CR63","doi-asserted-by":"crossref","first-page":"881801","DOI":"10.3389\/fonc.2022.881801","volume":"12","author":"L Dai","year":"2022","unstructured":"Dai L, Tao Y, Shi Z, Liang W, Hu W, Xing Z, Zhou S, Guo X, Fu X, Wang X. SOCS3 acts as an Onco-immunological biomarker with value in assessing the tumor Microenvironment, pathological Staging, histological Subtypes, therapeutic Effect, and prognoses of several types of cancer. Front Oncol. 2022;12:881801.","journal-title":"Front Oncol"},{"issue":"10","key":"15345_CR64","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s43018-023-00620-0","volume":"4","author":"S Goswami","year":"2023","unstructured":"Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, et al. Myeloid-specific KDM6B Inhibition sensitizes glioblastoma to PD1 Blockade. Nat Cancer. 2023;4(10):1455\u201373.","journal-title":"Nat Cancer"},{"issue":"1","key":"15345_CR65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79(1):109\u201325.","journal-title":"J Hepatol"},{"issue":"1","key":"15345_CR66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","volume":"5","author":"P Neri","year":"2024","unstructured":"Neri P, Barwick BG, Jung D, Patton JC, Maity R, Tagoug I, Stein CK, Tilmont R, Leblay N, Ahn S, et al. ETV4-Dependent transcriptional plasticity maintains MYC expression and results in imid resistance in multiple myeloma. Blood Cancer Discovery. 2024;5(1):56\u201373.","journal-title":"Blood Cancer Discovery"},{"issue":"2","key":"15345_CR67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/ol.2021.13159","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Sun C, Li J, Jiang H, Qiu Y, Gong M. Knockdown of ETV4 promotes autophagy-dependent apoptosis in GBM cells by reducing the transcriptional activation of EMP1. Oncol Lett. 2022;23(2):41.","journal-title":"Oncol Lett"},{"issue":"4","key":"15345_CR68","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbrc.2017.03.163","volume":"486","author":"J Xiao","year":"2017","unstructured":"Xiao J, Yang S, Shen P, Wang Y, Sun H, Ji F, Zhou D. Phosphorylation of ETV4 at Ser73 by ERK kinase could block ETV4 ubiquitination degradation in colorectal cancer. Biochem Biophys Res Commun. 2017;486(4):1062\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"15345_CR69","first-page":"e2205613","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Liu S, Wang H, Xiao K, Lu J, Chen S, Huang M, Xie R, Lin T, Chen X. ETV4 mediated Tumor-Associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder Cancer. Advanced science (Weinheim. Baden-Wurttemberg Germany). 2023;10(11):e2205613.","journal-title":"Baden-Wurttemberg Germany)"},{"issue":"3","key":"15345_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2024.8776","volume":"52","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Jiang T, Wang J. Role of LMO7 in cancer. Oncol Rep. 2024;52(3):1\u201312.","journal-title":"Oncol Rep"},{"issue":"6","key":"15345_CR71","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3892\/etm.2011.329","volume":"2","author":"H Nakamura","year":"2011","unstructured":"Nakamura H, Hori K, Tanaka-Okamoto M, Higashiyama M, Itoh Y, Inoue M, Morinaka S, Miyoshi J. Decreased expression of LMO7 and its clinicopathological significance in human lung adenocarcinoma. Experimental Therapeutic Med. 2011;2(6):1053\u20137.","journal-title":"Experimental Therapeutic Med"},{"issue":"2","key":"15345_CR72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41418-024-01358-7","volume":"32","author":"S Dai","year":"2025","unstructured":"Dai S, Peng Y, Wang G, Chen C, Chen Q, Yin L, Yan H, Zhang K, Tu M, Lu Z, et al. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Cell Death Differ. 2025;32(2):271\u201390.","journal-title":"Cell Death Differ"},{"issue":"6","key":"15345_CR73","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062\u201378.","journal-title":"Cell"},{"issue":"1","key":"15345_CR74","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"15345_CR75","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1189\/jlb.3A1215-554RR","volume":"100","author":"P Gordon","year":"2016","unstructured":"Gordon P, Okai B, Hoare JI, Erwig LP, Wilson HM. SOCS3 is a modulator of human macrophage phagocytosis. J Leukoc Biol. 2016;100(4):771\u201380.","journal-title":"J Leukoc Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15345-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:34:22Z","timestamp":1767627262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15345"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15345-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6838293\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study investigated the publicly available data, and no ethical approval was required. All methods were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}